Key result
Long-term antihypertensive treatment reduced PP/SVi by up to 16% at 3 years, which did not significantly impact LV mass index but correlated with LV remodeling toward eccentric geometry.
Why the study?
Does long-term antihypertensive treatment reduce PP/SVi, and does this reduction impact left ventricular mass and geometry in hypertensive subjects?
RCT
Does long-term antihypertensive treatment reduce PP/SVi, and does this reduction impact left ventricular mass and geometry in hypertensive subjects?
Long-term antihypertensive treatment reduces arterial stiffness as measured by PP/SVi, which correlates with favorable left ventricular remodeling toward eccentric geometry (lower relative wall thickness) but not with changes in LV mass index.
Does not support changing LV assessment in hypertension; hypothesis-generating for eccentric remodeling, needing RCTs.
BACKGROUND: In cross-sectional data in hypertensive subjects, brachial pulse pressure (PP)/Doppler stroke index (SVi), (PP/SVi) correlates weakly but significantly with left ventricular (LV) mass and relative wall thickness (RWT). METHODS: In the Losartan Intervention For End-point reduction in hypertension (LIFE) study, we evaluated the impact of antihypertensive treatment on change of PP/SVi as raw indicator of systemic arterial stiffness, and further explored the impact of the change in PP/SVi on the change in LV mass and RWT. RESULTS: Compared to baseline, mean PP/SVi reduction was -13% at year 1, -15% at year 2, and -16% at year 3 follow-up, and was sustained through year 4 and year 5 follow-ups; change in PP/SVi was related to increased SVi and decreased PP during the annual follow-ups, but not to LV mass change. Restricting analyses to the first two follow-ups to ensure highest statistical power, age >65 and diabetes were associated with higher PP/SVi at baseline and throughout follow-ups; black participants and women had baseline PP/SVi mean values comparable with those of their counterparts, showed blunted PP/SVi reduction after 1 year, but differences became smaller and not statistically significant at year 2 follow-up. Losartan- or atenolol-based treatments were associated with comparable reduction of PP/SVi. At year 2 follow-up, reduced PP/SVi was associated with greater reductions in mean blood pressure (BP) and heart rate and greater increase in SVi, but not with lower LV mass; RWT was lower with lower PP/SVi at year 2 follow-up. CONCLUSIONS: Reduction in PP/SVi by long-term antihypertensive treatment did not have significant impact on change in LV mass index, but correlated with LV remodeling toward eccentric geometry.
No takes yet. Share an insight, caveat, or question.
Palmieri et al. (2008) conducted an RCT in Hypertension. Losartan- or atenolol-based treatments vs. Baseline was evaluated on Change in PP/SVi and its impact on LV mass and relative wall thickness (RWT). Long-term antihypertensive treatment reduced PP/SVi by up to 16% at 3 years, which did not significantly impact LV mass index but correlated with LV remodeling toward eccentric geometry.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: